Immuno-PET Imaging of Tumor Mesothelin Expression with a Gallium-68 Radiolabeled Nanobody
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Xiaoying Lv und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Positron-Emission Tomography, GPI-Linked Proteins, Single-Domain Antibodies. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Mesothelin (MSLN) is overexpressed in various solid tumors but limited in normal tissues, making it a promising candidate for molecular imaging and targeted therapy. Nanobodies, the smallest antibody derived fragments, are facile to modify for functional agent conjugation. With radionuclides, nanobody-based immunopositron emission tomography (immuno-PET) will provide valuable whole-body information for analysis of related target properties. The objective of this work was to evaluate the in vivo distribution peculiarity of 68Ga-NOTA-MS3 as an MSLN-overexpressing tumor-directing probe. After rigorous quality control, xenograft models exhibiting differential MSLN expression were constructed for in vivo behavior evaluation of 68Ga-NOTA-MS3. In addition, to improve the visualization of intra-abdominal tumors and mitigate potential radiation-related nephrotoxicity, a strategy involving preadministration of sodium maleate was employed to reduce the renal uptake of 68Ga-NOTA-MS3. The nondecay corrected radiolabeling yield of 68Ga-NOTA-MS3 was approximately 47%, and the radiochemical purity was >98%. Both immuno-PET imaging and biodistribution studies revealed that the uptake of 68Ga-NOTA-MS3 was high in BxPC-3 and OVCAR-3 tumors, while HuH-7 tumors showed low uptake. These results aligned with the MSLN expression assessment. Moreover, 2 h postinjection of the imaging agent was identified as the optimal timing for immuno-PET. Furthermore, the preadministration of sodium maleate significantly reduced the renal accumulation of 68Ga-NOTA-MS3 (from 61.14 ± 7.57%ID/g to 4.31 ± 1.31%ID/g), hence ameliorating the delineation of orthotopic pancreatic tumors. The study validates 68Ga-NOTA-MS3 as an effective probe for the precise, noninvasive imaging of MSLN, which, in turn, allows for the accurate diagnosis of MSLN-expressing lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
- Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan 430022, China.
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
ORCID-Profile: Xiaoying Lv, Dawei Jiang, Yongkang Gai, Weijun Wei, Xiaoli Lan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lv, X., Deng, Y., Song, X., Zheng, D., Lin, Z., Wu, Z., Jiang, D., Gai, Y., Wei, W., & Lan, X. (2026). Immuno-PET Imaging of Tumor Mesothelin Expression with a Gallium-68 Radiolabeled Nanobody. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01204
Vancouver
Lv X, Deng Y, Song X, Zheng D, Lin Z, Wu Z, et al. Immuno-PET Imaging of Tumor Mesothelin Expression with a Gallium-68 Radiolabeled Nanobody. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01204
BibTeX
@article{Lv2026,
author = {Lv, Xiaoying and Deng, Yueling and Song, Xiangming and Zheng, Danzha and Lin, Zhaoguo and Wu, Zaijie and Jiang, Dawei and Gai, Yongkang and Wei, Weijun and Lan, Xiaoli},
title = {Immuno-PET Imaging of Tumor Mesothelin Expression with a Gallium-68 Radiolabeled Nanobody},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01204}
}
EUVIMED